Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Biological/Vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| VX-880 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Biological/Vaccine | BIOLOGICAL | Infused into the hepatic portal vein. |
Key Inclusion Criteria: * Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence * Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks * Consistent use of continuous glucose monito...
VX-880 is an investigational therapy being studied for the treatment of type 1 diabetes in patients who have also received a kidney transplant. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
VX-880 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting a Phase 3 clinical trial to evaluate the therapy in patients with type 1 diabetes and a kidney transplant.
VX-880 is in Phase 3 clinical development. It is an investigational therapy and has not yet been approved for commercial use. The ongoing Phase 3 trial is currently recruiting participants.
VX-880 is being studied in a Phase 3 clinical trial with the identifier NCT06832410. This trial is evaluating the efficacy, safety, and tolerability of VX-880 in participants with type 1 diabetes who have a kidney transplant. The study is currently recruiting and aims to enroll 10 participants.
VX-880 is described as a biological therapy, specifically a monoclonal antibody. It is being investigated as a treatment for type 1 diabetes in patients with a kidney transplant. It is not a vaccine; it is a therapeutic biologic in clinical development.